Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2NCT00265200
Official study title

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Study summary

The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedzoledronic acid

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 5, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Louisville

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 2
Sponsor
University of Louisville
Interventions being studied
Drug: zoledronic acid
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • invasive lung cancer (small cell or non-small cell lung cancer)
  • osteolytic bone metastasis determined by clinical exam, bone scan/XR
  • age \> 18 years
Reasons someone may not be able to joinExclusion criteria
  • concurrent malignancy with a second primary
  • renal failure (serum creatinine \> 3mg/dl)
  • pregnancy
  • active rheumatoid arthritis
  • intolerance to zoledronic acid

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • James Graham Brown Cancer CenterLouisville, Kentucky

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2018. Always confirm current availability with the study team.

View original record ↗